{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:36:47Z","timestamp":1788824207104,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Eye-Lens Pte., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s10384-023-01012-8","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T11:02:55Z","timestamp":1691406175000},"page":"602-611","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Assessment of myopic rebound effect after discontinuation of treatment with 0.01% atropine eye drops in Japanese school-age children"],"prefix":"10.1007","volume":"67","author":[{"given":"Osamu","family":"Hieda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Fujikado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ishiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hasebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemasa","family":"Torii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The ATOM-J Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Sotozono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Oshika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohji","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Seok","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Tokutake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyo","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Shigeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihide","family":"Kurihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuno","family":"Negishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Tsubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"key":"1012_CR1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","volume":"123","author":"BA Holden","year":"2016","unstructured":"Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123:1036\u201342.","journal-title":"Ophthalmology"},{"key":"1012_CR2","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12886-020-01410-3","volume":"20","author":"Z Xie","year":"2020","unstructured":"Xie Z, Long Y, Wang J, Li Q, Zhang Q. Prevalence of myopia and associated risk factors among primary students in Chongqing: multilevel modeling. BMC Ophthalmol. 2020;20:146.","journal-title":"BMC Ophthalmol"},{"key":"1012_CR3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/OPX.0000000000001367","volume":"96","author":"MA Bullimore","year":"2019","unstructured":"Bullimore MA, Brennan NA. Myopia control: why each diopter matters. Optom Vis Sci. 2019;96:463\u20135.","journal-title":"Optom Vis Sci"},{"key":"1012_CR4","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.ophtha.2021.04.032","volume":"128","author":"MA Bullimore","year":"2021","unstructured":"Bullimore MA, Ritchey ER, Shah S, Leveziel N, Bourne RRA, Flitcroft DI. The risks and benefits of myopia control. Ophthalmology. 2021;128:1561\u201379.","journal-title":"Ophthalmology"},{"key":"1012_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.111092","volume":"133","author":"WY Wang","year":"2021","unstructured":"Wang WY, Chen C, Chang J, Chien L, Shih YF, Lin LLK, et al. Pharmacotherapeutic candidates for myopia: a review. Biomed Pharmacother. 2021;133: 111092.","journal-title":"Biomed Pharmacother"},{"key":"1012_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004916.pub3:CD004916","author":"JJ Walline","year":"2011","unstructured":"Walline JJ, Lindsley K, Vedula SS, Cotter SA, Mutti DO, Twelker JD. Interventions to slow progression of myopia in children. Cochrane Database Syst Rev. 2011. https:\/\/doi.org\/10.1002\/14651858.CD004916.pub3:CD004916.","journal-title":"Cochrane Database Syst Rev"},{"key":"1012_CR7","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/eye.2012.279","volume":"27","author":"YT Fang","year":"2013","unstructured":"Fang YT, Chou YJ, Pu C, Lin PJ, Liu TL, Huang N, et al. Prescription of atropine eye drops among children diagnosed with myopia in Taiwan from 2000 to 2007: a nationwide study. Eye (Lond). 2013;27:418\u201324.","journal-title":"Eye (Lond)"},{"key":"1012_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","volume":"119","author":"A Chia","year":"2012","unstructured":"Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012;119:347\u201354.","journal-title":"Ophthalmology"},{"key":"1012_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","volume":"126","author":"JC Yam","year":"2019","unstructured":"Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology. 2019;126:113\u201324.","journal-title":"Ophthalmology"},{"key":"1012_CR10","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","volume":"113","author":"WH Chua","year":"2006","unstructured":"Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL, et al. Atropine for the treatment of childhood myopia. Ophthalmology. 2006;113:2285\u201391.","journal-title":"Ophthalmology"},{"key":"1012_CR11","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.ophtha.2008.10.020","volume":"116","author":"L Tong","year":"2009","unstructured":"Tong L, Huang XL, Koh AL, Zhang X, Tan DT, Chua WH. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine. Ophthalmology. 2009;116:572\u20139.","journal-title":"Ophthalmology"},{"key":"1012_CR12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ajo.2013.09.020","volume":"157","author":"A Chia","year":"2014","unstructured":"Chia A, Chua WH, Wen L, Fong A, Goon YY, Tan D. Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%. Am J Ophthalmol. 2014;157:451-7.e1.","journal-title":"Am J Ophthalmol"},{"key":"1012_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100923","volume":"83","author":"NA Brennan","year":"2021","unstructured":"Brennan NA, Toubouti YM, Cheng X, Bullimore MA. Efficacy in myopia control. Prog Retin Eye Res. 2021;83: 100923.","journal-title":"Prog Retin Eye Res"},{"key":"1012_CR14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","volume":"123","author":"A Chia","year":"2016","unstructured":"Chia A, Lu QS, Tan D. Five-year clinical trial on Atropine for the Treatment of Myopia 2: myopia control with atropine 0.01% eyedrops. Ophthalmology. 2016;123:391\u20139.","journal-title":"Ophthalmology"},{"key":"1012_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10384-021-00822-y","volume":"65","author":"O Hieda","year":"2021","unstructured":"Hieda O, Hiraoka T, Fujikado T, Ishiko S, Hasebe S, Torii H, et al. Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study. Jpn J Ophthalmol. 2021;65:315\u201325.","journal-title":"Jpn J Ophthalmol"},{"key":"1012_CR16","first-page":"79","volume":"197","author":"M Salazar","year":"1976","unstructured":"Salazar M, Shimada K, Patil PN. Iris pigmentation and atropine mydriasis. J Pharmacol Exp Ther. 1976;197:79\u201388.","journal-title":"J Pharmacol Exp Ther"},{"key":"1012_CR17","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","volume":"138","author":"S Wei","year":"2020","unstructured":"Wei S, Li SM, An W, Du J, Liang X, Sun Y, et al. Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children: a randomized clinical trial. JAMA Ophthalmol. 2020;138:1178\u201384.","journal-title":"JAMA Ophthalmol"},{"key":"1012_CR18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","volume":"129","author":"JC Yam","year":"2022","unstructured":"Yam JC, Zhang XJ, Zhang Y, Wang YM, Tang SM, Li FF, et al. Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: continued versus washout: phase 3 report. Ophthalmology. 2022;129:308\u201321.","journal-title":"Ophthalmology"},{"key":"1012_CR19","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1167\/iovs.11-8453","volume":"53","author":"T Hiraoka","year":"2012","unstructured":"Hiraoka T, Kakita T, Okamoto F, Takahashi H, Oshika T. Long-term effect of overnight orthokeratology on axial length elongation in childhood myopia: a 5-year follow-up study. Invest Ophthalmol Vis Sci. 2012;53:3913\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1012_CR20","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1167\/iovs.10-5485","volume":"52","author":"T Kakita","year":"2011","unstructured":"Kakita T, Hiraoka T, Oshika T. Influence of overnight orthokeratology on axial elongation in childhood myopia. Investig Ophthalmol Vis Sci. 2011;52:2170\u20134.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1012_CR21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/OPX.0000000000001873","volume":"99","author":"P Chamberlain","year":"2022","unstructured":"Chamberlain P, Bradley A, Arumugam B, Hammond D, McNally J, Logan NS, et al. Long-term effect of dual-focus contact lenses on myopia progression in children: a 6-year multicenter clinical trial. Optom Vis Sci. 2022;99:204\u201312.","journal-title":"Optom Vis Sci"},{"key":"1012_CR22","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1136\/bjophthalmol-2018-313739","volume":"104","author":"CSY Lam","year":"2020","unstructured":"Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104:363\u20138.","journal-title":"Br J Ophthalmol"},{"key":"1012_CR23","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ophtha.2021.11.023","volume":"129","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Zhu Z, Tan X, Kong X, Zhong H, Zhang J, et al. Effect of repeated low-level red-light therapy for myopia control in children: a multicenter randomized trial. Ophthalmology. 2022;129:509\u201319.","journal-title":"Ophthalmology"},{"key":"1012_CR24","doi-asserted-by":"publisher","first-page":"12750","DOI":"10.1038\/s41598-020-69710-8","volume":"10","author":"N Kinoshita","year":"2020","unstructured":"Kinoshita N, Konno Y, Hamada N, Kanda Y, Shimmura-Tomita M, Kaburaki T, et al. Efficacy of combined orthokeratology and 0.01% atropine solution for slowing axial elongation in children with myopia: a 2-year randomised trial. Sci Rep. 2020;10:12750.","journal-title":"Sci Rep"},{"key":"1012_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2022-321272","author":"S Xu","year":"2022","unstructured":"Xu S, Li Z, Zhao W, Zheng B, Jiang J, Ye G, et al. Effect of atropine, orthokeratology and combined treatments for myopia control: a 2-year stratified randomised clinical trial. Br J Ophthalmol. 2022. https:\/\/doi.org\/10.1136\/bjo-2022-321272.","journal-title":"Br J Ophthalmol"},{"key":"1012_CR26","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.exer.2014.10.003","volume":"128","author":"BP Sander","year":"2014","unstructured":"Sander BP, Collins MJ, Read SA. The effect of topical adrenergic and anticholinergic agents on the choroidal thickness of young healthy adults. Exp Eye Res. 2014;128:181\u20139.","journal-title":"Exp Eye Res"},{"key":"1012_CR27","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ajo.2021.12.014","volume":"237","author":"JC Yam","year":"2022","unstructured":"Yam JC, Jiang Y, Lee J, Li S, Zhang Y, Sun W, et al. The association of choroidal thickening by atropine with treatment effects for myopia: two-year clinical trial of the LAMP Study. Am J Ophthalmol. 2022;237:130\u20138.","journal-title":"Am J Ophthalmol"},{"key":"1012_CR28","first-page":"1535","volume":"104","author":"A Fu","year":"2020","unstructured":"Fu A, Stapleton F, Wei L, Wang W, Zhao B, Watt K, et al. Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression. Br J Ophthalmol. 2020;104:1535\u201341.","journal-title":"Br J Ophthalmol"},{"key":"1012_CR29","first-page":"15","volume":"61","author":"L Ye","year":"2020","unstructured":"Ye L, Shi Y, Yin Y, Li S, He J, Zhu J, et al. Effects of atropine treatment on choroidal thickness in myopic children. Investig Ophthalmol Vis Sci. 2020;61:15\u201325.","journal-title":"Investig Ophthalmol Vis Sci"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-023-01012-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-023-01012-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-023-01012-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T01:04:50Z","timestamp":1693443890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-023-01012-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1012"],"URL":"https:\/\/doi.org\/10.1007\/s10384-023-01012-8","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,7]]},"assertion":[{"value":"27 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O. Hieda, Provision of drugs, translation and submission of this article (Eye-Lens Pte., Ltd); T. Hiraoka, None; T. Fujikado, None; S. Ishiko, None; S. Hasebe, None; H. Torii, None; H. Takahashi, None; S. Tanaka, Consulting fees (Daiichi-Sankyo, Satt, Welby, Eli Lilly), Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Bayer, Research Institute of Healthcare Data Science, Amgen); S. Kinoshita, Grants or contracts (Santen, Senju, HOYA), Consulting fees (Santen, Alcon, At Working), Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Santen, Senju, Alcon, Johnson & Johnson Vision, At Working).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}